STOCK TITAN

Shoulder Innovations (SI) Stock Price, News & Analysis

SI NYSE
Published by Stock Titan Data refreshed

Price Move History

Daily moves over 5%
37 252 sessions, November 6, 2025 to November 6, 2026
Largest daily move
+32% close of November 12, 2025
1-year change
+83.1% closing prices, November 6, 2025 to November 6, 2026
1-month change
+7.3% closing prices, October 6, 2026 to November 6, 2026

Company Description

Shoulder Innovations, Inc. (NYSE: SI) is described as a commercial-stage medical technology company that is exclusively focused on transforming the shoulder surgical care market. According to the company’s public statements, its business centers on advanced implant systems for shoulder arthroplasty and related enabling technologies that support surgeons and patients across different sites of care.

The company’s implant systems for shoulder arthroplasty are presented as a core element of a broader Shoulder Innovations ecosystem. This ecosystem is described as being designed to improve key components of shoulder surgical care, including preoperative planning, implant design and procedural efficiency. By concentrating on these areas, the company states that it aims to benefit each stakeholder in the care chain involved in shoulder surgery.

Business focus and ecosystem

Shoulder Innovations emphasizes that its ecosystem is comprised of several elements: advanced implant systems for shoulder arthroplasty, enabling technologies, efficient instrument systems, specialized support and surgeon-to-surgeon collaboration. In its public communications, the company explains that these elements are intended to work together to address long-standing clinical and operational challenges in the shoulder surgical care market.

Across multiple disclosures, Shoulder Innovations highlights goals such as delivering predictable outcomes, procedural simplicity and efficiency across all sites of care. The company’s focus on shoulder arthroplasty and related technologies positions it within the medical technology and orthopedic implant space, even though some third-party classification data may list it under other sectors.

Products and technology areas

Based on available descriptions, Shoulder Innovations’ current offering centers on advanced implant systems for shoulder arthroplasty. The company also refers to enabling technologies and digital solutions that are associated with its ecosystem. In its financial and corporate updates, Shoulder Innovations notes that the number of implant systems sold is a key business metric it uses to evaluate demand for its implant systems, generate net revenue and expand its business.

In addition to implant systems, the company references efficient instrument systems and specialized support for surgeons, as well as collaboration among surgeons. These components are described as part of the overall approach to improving preoperative planning, implant design and procedural efficiency in shoulder surgery.

Strategic initiatives and partnerships

In a press release furnished in a Form 8-K, Shoulder Innovations announced a strategic partnership with Interventional Systems (INS), a developer of robotic solutions for minimally invasive surgery. The partnership is described as being focused on introducing a shoulder-specific micro-robotic solution intended to enhance shoulder surgical precision and workflow efficiency in total shoulder arthroplasty and reverse shoulder arthroplasty.

The company states that, once developed, this robotic solution is expected to integrate with its ProVoyance platform to form a comprehensive enabling technology solution. The stated goals include improving surgical accuracy and workflow and meeting the needs of patients and surgeons across all sites of care, particularly ambulatory surgery centers. The company also notes that the robotic system is designed to be transported directly into the operating room as a portable unit.

Market and operating context

In its financial result announcements, Shoulder Innovations repeatedly characterizes itself as a commercial-stage company with a focus on advanced implant systems for anatomic and reverse total shoulder arthroplasty. The company highlights metrics such as net revenue, gross margin and the number of implant systems sold as indicators of business performance, while also discussing investments in research and development for new product development efforts.

Shoulder Innovations also notes that it has completed an initial public offering and a convertible notes financing, and that it reports financial results for quarters ended June 30 and September 30, 2025. The company uses non-GAAP measures such as Adjusted EBITDA, with explanations of how these measures are defined and their limitations as analytical tools.

Regulatory status and corporate information

According to its Form 8-K filings, Shoulder Innovations, Inc. is incorporated in Delaware and files reports with the U.S. Securities and Exchange Commission under Commission File Number 001-42771. The filings list Grand Rapids, Michigan as the location associated with the company’s principal offices. The company’s common stock trades on the New York Stock Exchange under the symbol SI.

The Form 8-K filings describe events such as the release of quarterly financial results, the furnishing of earnings press releases and conference call transcripts, and the announcement of the partnership with Interventional Systems. These filings also clarify that certain information, including attached press releases and transcripts, is furnished rather than filed for purposes of specific sections of the Securities Exchange Act of 1934.

Approach to clinical and operational challenges

In multiple public statements, Shoulder Innovations explains that its ecosystem is intended to address long-standing clinical and operational challenges in the shoulder surgical care market. The company describes its objectives as delivering predictable outcomes, procedural simplicity and efficiency. It also emphasizes the role of surgeon-to-surgeon collaboration and specialized support as part of its approach to supporting shoulder specialists and their patients.

By focusing exclusively on shoulder surgical care and shoulder arthroplasty, Shoulder Innovations presents itself as a company with a specialized focus within the broader medical technology landscape. Its disclosures highlight the combination of implant systems, enabling technologies, instrument systems and support services that together form its stated ecosystem for shoulder surgical care.

Stock Performance

$20.54
+0.83%
+0.17
Last updated: November 6, 2026 at 16:00
+83.1%
Performance 1 year
$429.7M

Shoulder Innovations (SI) closed at $20.54 on November 6, 2026. Over the past 12 months, the price has gained 83.1%.

See what a $1,000 investment in SI would be worth today

Average down calculator for SI

SI Metrics & Rankings

Price returns through November 6, 2026. Month and year figures include the first trading day. Ranking links may use different dates.

Latest News

Shoulder Innovations has 10 recent news articles, with the latest published 3 days ago. Of the recent coverage, 3 articles coincided with positive price movement and 6 with negative movement. Key topics include earnings, conferences, earnings date, fda approval, partnership. View all SI news →

Insider Radar

Net Sellers
90-Day Summary
0
Shares Bought
58,968
Shares Sold
8
Transactions
Most Recent Transaction
Ball Robert Joseph (CEO & Executive Chairman) sold 10,175 shares @ $18.45 on September 14, 2026

Insider selling at Shoulder Innovations over the past 90 days can reflect routine portfolio management, scheduled trading plans (Rule 10b5-1), tax planning, or compensation-related dispositions rather than a directional view on the stock.

Based on SEC Form 4 filings over the last 90 days.

Financial Highlights

Shoulder Innovations generated $47.3M in revenue in FY2025, retaining a 76.5% gross margin, operating income reached -$26.3M (-55.6% operating margin), and net income was -$40.4M, reflecting a -85.3% net profit margin. Diluted earnings per share stood at -$4.65. The company generated -$28.6M in operating cash flow. The current ratio was 11.07, measuring current assets divided by current liabilities.

$47.3M
Revenue (FY2025)
-$40.4M
Net Income (FY2025)
-$28.6M
Operating Cash Flow

Upcoming Events

NOV
10
November 10, 2026 Marketing

UBS fireside chat

Fireside chat at UBS Global Healthcare Conference in Palm Beach Gardens, FL, 3:30–4:05 PM EST; webcast on company IR site.
NOV
17
November 17, 2026 Marketing

Jefferies fireside chat

Hybrid presentation and fireside chat at Jefferies Global Healthcare Conference in London, 11:30–11:55 AM EST; webcast available.

Shoulder Innovations has 2 upcoming scheduled events. The next event, "UBS fireside chat", is scheduled for November 10, 2026 (in 2 days). Investors can track these dates to stay informed about potential catalysts that may affect the SI stock price.

Short Interest History

Last 12 Months

Short interest in Shoulder Innovations (SI) currently stands at 710.1 thousand shares, up 12.7% from the previous reporting period, representing 3.7% of the float. Since November 2025, short interest has increased by 196.9%.

Days to Cover History

Last 12 Months

Days to cover for Shoulder Innovations (SI) currently stands at 6.3 days, up 64.5% from the previous period. The ratio is the reported short interest divided by the average daily trading volume. Since November 2025, the figure has increased by 167.9%. Across the settlements charted above, it has ranged from 1.0 to 7.6 days.

SI Company Profile & Sector Positioning

Shoulder Innovations (SI) and is listed on the NYSE.

Frequently Asked Questions

The current stock price of Shoulder Innovations (SI) is $20.54 as of November 6, 2026.

The market cap of Shoulder Innovations (SI) is approximately $429.7M. Learn more about what market capitalization means .

The FY2025 revenue of Shoulder Innovations (SI) is $47.3M, from its most recent completed fiscal year.

The FY2025 net income of Shoulder Innovations (SI) is -$40.4M, from its most recent completed fiscal year.

The diluted earnings per share (EPS) of Shoulder Innovations (SI) is -$4.65 for FY2025, its most recent completed fiscal year. Learn more about EPS .

The operating cash flow of Shoulder Innovations (SI) is -$28.6M for FY2025, its most recent completed fiscal year. Learn about cash flow.

The net profit margin of Shoulder Innovations (SI) is -85.3% for FY2025, its most recent completed fiscal year. Learn about profit margins.

The operating profit margin of Shoulder Innovations (SI) is -55.6% for FY2025, its most recent completed fiscal year. Learn about operating margins.

The gross profit margin of Shoulder Innovations (SI) is 76.5% for FY2025, its most recent completed fiscal year. Learn about gross margins.

The current ratio of Shoulder Innovations (SI), current assets divided by current liabilities, was 11.07 at the end of FY2025, its most recent completed fiscal year. Learn about liquidity ratios.

The gross profit of Shoulder Innovations (SI) is $36.2M for FY2025, its most recent completed fiscal year.

The operating income of Shoulder Innovations (SI) is -$26.3M for FY2025, its most recent completed fiscal year. Learn about operating income.

Shoulder Innovations, Inc. is described as a commercial-stage medical technology company exclusively focused on transforming the shoulder surgical care market. Its current offering centers on advanced implant systems for shoulder arthroplasty, supported by enabling technologies, instrument systems, specialized support and surgeon-to-surgeon collaboration.

The company’s core focus is on shoulder surgical care, particularly shoulder arthroplasty. It highlights advanced implant systems for shoulder arthroplasty as a core element of its ecosystem, which is designed to improve preoperative planning, implant design and procedural efficiency.

Shoulder Innovations describes its ecosystem as being comprised of advanced implant systems for shoulder arthroplasty, enabling technologies, efficient instrument systems, specialized support and surgeon-to-surgeon collaboration. According to the company, these elements are intended to address clinical and operational challenges in shoulder surgical care.

According to its SEC filings and press releases, Shoulder Innovations, Inc. is listed on the New York Stock Exchange under the ticker symbol SI.

Form 8-K filings for Shoulder Innovations, Inc. list Grand Rapids, Michigan as the location associated with the company’s principal offices.

In its financial disclosures, Shoulder Innovations states that the number of implant systems sold is a key business metric and a useful indicator of its ability to drive demand for its implant systems, generate net revenue and expand its business.

The company reports metrics such as net revenue, gross margin, operating loss and net loss in its quarterly financial results. It also provides non-GAAP measures like Adjusted EBITDA, along with reconciliations to net loss and explanations of the limitations of these measures.

In a press release furnished in a Form 8-K, Shoulder Innovations announced a strategic partnership with Interventional Systems to introduce a shoulder-specific micro-robotic solution. The partnership is intended to enhance shoulder surgical precision and workflow efficiency in total shoulder arthroplasty and reverse shoulder arthroplasty and is expected to integrate with the company’s ProVoyance platform.

The company states that its ecosystem seeks to address long-standing clinical and operational challenges in the shoulder surgical care market by delivering predictable outcomes, procedural simplicity and efficiency across all sites of care.

Shoulder Innovations uses non-GAAP metrics such as Adjusted EBITDA, which it defines as net loss before interest expense, income tax expense, depreciation and amortization and stock-based compensation expense. The company explains that it uses these measures to evaluate and compare financial and operational performance over multiple periods, while also noting the limitations of such measures.